34.62
-0.09%
Close of 9 Nov 2026, in CNY
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About CSPC Innovation Pharmaceutical Co
Its shares trade on Shenzhen under the ticker 300765.SZ. It has been listed since 22 March 2019. In the fiscal year to 31 December 2025, it reported revenue of CN¥2.15bn and a net loss of CN¥241.1m. At that date it held total assets of CN¥6.28bn and shareholders' equity of CN¥2.67bn.
CSPC Innovation Pharmaceutical Co., Ltd. manufactures and sells active pharmaceutical ingredient, including caffeine, theophylline, aminophylline, diprophylline, theobromine, pentoxifylline, doxofylline, psychotropic drugs (caffeine) and food additives (caffeine). The company is headquartered in Shijiazhuang, Hebei. The company went IPO on 2019-03-22. The firm's main products include caffeine products, vitamin products and other functional foods. The Company’s caffeine products are mainly caffeine, including a small amount of theophylline, aminophylline and theobromine. The vitamin products are mainly vitamin C tablets, including a small amount of vitamin C drinks. The firm mainly distributes its products both in the domestic market and to overseas markets.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Pharmaceuticals
- Listed since
- 22 Mar 2019
- Employees
- 1,945
- Website
- xnwpharma.net ↗
Leadership
Pay as last reported
- Mr. Bing YaoChairman of the Board, General Manager, since 2023CN¥538,400
- Mr. Long DaiChief Financial Officer, Secretary of the Board, Director, since 2023CN¥223,200
- Mr. Xiwu HuiDeputy General Manager
- Mr. Lei CaiDirector
- Mr. Feng HanDirector, since 2017CN¥484,100
- Ms. Wen XuDirector
- Ms. Congzhi DiIndependent DirectorCN¥60,000
- Mr. Dibin LiIndependent DirectorCN¥60,000
- Mr. Peng YangIndependent DirectorCN¥60,000
- Mr. Jianping ZhouIndependent DirectorCN¥35,000
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 59
- Environment
- 73
- Social
- 63
- Governance
- 41
- Direct emissions (scope 1)
- 4,867 t
- Energy emissions (scope 2)
- 295,500 t
- Women in the workforce
- 42.58142%
- Carbon reduction policy
- No
- Human rights policy
- Yes
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- CSPC Innovation Pharmaceutical Co Ltd operates in the Health Care sector with a focus on Pharmaceuticals.
- The company has an IPO date of March 22, 2019, indicating a publicly traded entity.
- CSPC Innovation Pharmaceutical Co Ltd is headquartered in Shijiazhuang, Hebei, China.
Weaknesses
- The company's product line is limited to caffeine products, vitamin products, and other functional foods.
- CSPC Innovation Pharmaceutical Co Ltd has only one main product segment: caffeine, including aminophylline and theobromine.
- The company's operations are constrained to the domestic market and overseas markets without specific regional details.
Opportunities
- CSPC Innovation Pharmaceutical Co Ltd can expand its product offerings beyond caffeine and vitamin products.
- The company has potential to grow in the pharmaceutical industry with its current focus on active pharmaceutical ingredients.
- CSPC Innovation Pharmaceutical Co Ltd can leverage its existing employee base of 1,945 to scale operations.
Threats
- CSPC Innovation Pharmaceutical Co Ltd faces competition in the pharmaceutical industry from other companies.
- The company's reliance on caffeine and vitamin products may limit its market reach.
- CSPC Innovation Pharmaceutical Co Ltd's operations are subject to regulatory changes in the pharmaceutical sector.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.